On January 27, 2021, Design Therapeutics, a biotechnology company developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the completion of a $125 million Series B financing. Wilson Sonsini Goodrich & Rosati advised Design Therapeutics on IP matters related to the financing.

The proceeds from the financing will be used to advance Design Therapeutics’ novel GeneTAC platform, which leverages the disease-modifying potential of genomic medicines with proprietary advances in transcriptional regulation chemistry to create a pipeline of GeneTAC molecules. The company’s initial focus is on developing medicines for the treatment of nucleotide repeat expansion disorders, including Friedreich ataxia, which is expected to enter clinical development in the first half of 2022, and myotonic dystrophy type-1.

The Wilson Sonsini team that advised Design Therapeutics on IP matters related to the transaction includes Mike Hostetler, Uale Taotafa, and Katrina Otrubova.

For more information, please see Design Therapeutics’ press release.